Connecticut abolished capital punishment in April 2012. That made Connecticut the 17^th state in this country to do so and the fifth state to end the death penalty after 2010.

Soon, the state will have a chance to do what no other abolitionist state has done. In its next legislative session, Connecticut will consider a bill that would ban the sale of drugs or materials for use in an execution by any business in the state.

Two state legislators, Sen. Saud Anwar and Rep. Joshua Elliott, are leading this effort. As they argue: “This legislation is the logical and moral extension of our commitment to end capital punishment in our state. We do not believe in the death penalty for us here in Connecticut, and we will not support it anywhere else.”

This is not the first time the Nutmeg State has tried to lead the way in the campaign to end America’s death penalty.

At the time it abolished capital punishment, its new law only prevented any new death sentences from being imposed. It left 11 men on the state’s death row awaiting execution.

Three years later, in 2015, the state Supreme Court decided by a 4–3 vote that applying the death penalty only for past cases was unconstitutional. Writing for the majority, Justice Richard Palmer wrote, “We are persuaded that, following its prospective abolition, this state’s death penalty no longer comports with contemporary standards of decency and no longer serves any legitimate penological purpose.”

The court found that it would be “cruel and unusual” to keep anyone on death row in a state that had “determined that the machinery of death is irreparable or, at the least, unbecoming to a civilized modern state.”

With this decision, not only did Connecticut get out of the execution business, but it also appeared at the time that the court’s decision would, as the New York Times put it, “influence high courts in other states … where capital punishment has recently been challenged under the theory that society’s mores have evolved, transforming what was once an acceptable step into an unconstitutional punishment.”

In fact, courts in Colorado and Washington soon followed the Connecticut example. At that point, it seemed that Connecticut’s involvement with the death penalty had come to an end.

Now, Anwar and Elliott are asking the state to again take the lead in trying to stop executions in states where the death penalty has not yet been abolished. The legislation they plan to introduce would, if passed, “prevent any Connecticut-based corporation from supplying drugs or other tools for executions.”

Before examining the rationale for this novel idea, let’s examine why it would be so significant. The recent history of lethal injection offers important clues.

From 1982, when the first execution by lethal injection was carried out, until 2009, every one of those executions proceeded using the same three-drug protocol. It involved a sedative, a paralytic, and a drug to stop the heart.

However, the post-2009 period witnessed the unraveling of the original lethal injection paradigm with its three-drug protocol. By 2016, no states were employing it. Instead, they were executing people with a variety of novel drugs or drug combinations.

The shift from one dominant drug protocol to many was made possible by the advent of a new legal doctrine that granted states wide latitude to experiment with their drugs. This doctrine began with a decision that said that legislatures could take whatever “steps they deem appropriate … to ensure humane capital punishment.”

Subsequently, developments in Europe and the United States made it very difficult for death penalty states to get reliable supplies of drugs for lethal injection. This was the result of efforts by groups like the British anti–death penalty group Reprieve, which launched its Stop Lethal Injection Project and targeted pharmaceutical companies and other suppliers of lethal injection drugs.

Companies selling drugs for executions found themselves on the receiving end of a shaming campaign. As a EuroNews report notes, in 2011, the European pharmaceutical company Lundbeck decided to stop distributing the drug pentobarbital “to prisons in U.S. states currently carrying out the death penalty by lethal injection.”

Later that year, the European Union banned the export of drugs that could be used for “capital punishment, torture, or other cruel, inhuman or degrading treatment or punishment.” EuroNews explains that “among the drugs that the EU banned in 2011 was sodium thiopental, another drug commonly used in US lethal injections as part of a three-drug method of execution.”

Around the same time, Hospira, an American company that produced sodium thiopental, issued a press release announcing that it had “decided to exit the market.” It did so, according to EuroNews, “amidst pressure from Italian authorities as the company’s production plant was based there.”

In 2016, as the New York Times notes, “the pharmaceutical giant Pfizer announced … that it had imposed sweeping controls on the distribution of its products to ensure that none are used in lethal injections, a step that closes off the last remaining open-market source of drugs used in executions.” That brought to 20 the number of American and European drug companies that have adopted such restrictions, citing either moral or business reasons.

The result was that death penalty states had to improvise to get the execution drugs they needed. As Maya Foa, who tracks drug companies for Reprieve, explained, “Executing states must now go underground if they want to get hold of medicines for use in lethal injection.”

By the end of 2020, states had used at least 10 distinct drug protocols in their executions. Some protocols were used multiple times, and some were used just once. Even so, the traditional three-drug protocol was all but forgotten: Its last use was in 2012.

Other death penalty states, like Alabama, have adopted new methods of execution. A few have revived previously discredited methods. Some, like Ohio, have stopped executing anyone, although the death penalty remains on the books.

This brings us back to Connecticut.

In an op-ed published in April of this year, Anwar and Elliott pointed out that Absolute Standards, a drug manufacturer based in their state, was supplying the execution drug pentobarbital to the federal government and other states. Pentobarbital, either alone or in combination with other drugs, has become a popular alternative to the traditional three-drug cocktail.

“Thanks to Absolute Standards, in his last year in office, Donald Trump was able to end a 17-year hiatus on federal executions and carry out a horrifying spree of 13 executions,” Anwar and Elliott wrote. “The company supplied the Trump administration pentobarbital, a drug that, when used in excess to kill, induces suffering akin to drowning.”

“Absolute Standards,” they explain, “is not a pharmaceutical corporation—it’s a chemical company that makes solution for machines. That’s why it’s flown under the radar since it began producing and supplying lethal injection drugs in 2018.”

Anwar and Elliott’s innovation in the campaign to end capital punishment has already paid dividends. Last week, the Intercept reported that the president of Absolute Standards told the publication that his company had stopped manufacturing pentobarbital.

However, the two legislators are going forward with their plan to introduce their bill during the 2025 legislative session.

As Anwar says, “I think that laws last longer than legislators and issues, and I feel that irrespective of [Absolute Standard’s] commitment, I am interested in having a law in the future … to make sure that we don’t have another similar situation that we learn about indirectly or directly five years, 10 years, 20 years from now.”

Connecticut should adopt the Anwar/Elliott proposal, and legislators in other abolitionist states should follow suit. They should prohibit pharmaceutical corporations, gas suppliers, medical equipment manufacturers, and other businesses in their states from letting their products and services be used in executions. If they do not believe that the death penalty is right for their state, they should not support it anywhere else.

Legislators in abolitionist states should use their power to block businesses from disseminating the instrumentalities of death. They should join Anwar and Elliott in saying, “There is no profit worth a human life.”

HARTFORD, Conn. (WTNH) — The United States Surgeon General declared gun violence a health emergency, and News 8 is taking a look at how these acts of violence impact healthcare workers in the state.

While Connecticut leads the rest of the United States in terms of gun laws, communities are still experiencing high rates of gun violence.

Firearms are the number one cause of death for youth in Hartford, according to Jennifer Martin, M.D., an emergency medicine doctor at Saint Francis Hospital.

“It is taxing on the entire medical staff,” Martin said. “From everyone who works in the emergency departments, the operating rooms, the surgical floors. Every single person it touches touches violence in that way and it wears on everybody.”

At Connecticut Children’s Medical Center, they have staff who will meet with families and victims of gun violence while they are still receiving medical care to discuss what happened and help them through the recovery process, Dr. Kevin Borrup, executive director of the hospital’s Injury Prevention Center, said.

Borrup said that the most effective time to intervene with a gun shot victim is at the bedside shortly after the incident, calling it the “golden hour” where people are more likely to receive help.

Saint Francis also has efforts to educate the community on gun violence prevention.

Sen. Richard Blumenthal (D-Conn) said that while the surgeon general’s declaration was a step in the right direction, he hopes that it is followed by action.

“We need real action to ban assault weapons, provide for better liability on the part of the gun manufacturers, red flag statutes,” Blumenthal said.

WESTMINSTER, Vt. (WCAX) – They may be considered a pest in Lake Champlain, but state wildlife officials say sea lamprey call the Connecticut River home.

While the population in Lake Champlain is controlled as a nuisance species, lampreys make up an important part of the Connecticut River ecosystem. Every year, sea lampreys spawn in the river as far upstream as Wilder Dam in the Upper Valley, and in many of the tributaries including the West, Williams, Black, and White Rivers.

In this week’s Wildlife Watch, Ike Bendavid traveled to Westminster, where Vermont Fish and Wildlife biologists are working to protect spawning habitat on the Saxtons River.

Copyright 2024 WCAX. All rights reserved.